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Summary: Serum aspartate aminotransferase isoenzymes were measured in 123 hospital patients with various
liver diseases, using a new and simple immunochemical method.
Our findings show the usefulness of this determination in estimating the severity of hepatic damage, especially
if accompanied by the measurement of other mitochondrial enzymes/During hepatic damage, the cytoplasmic
isoenzyme is found in greater quantities than the mitochondrial isoenzyme, but the level of the latter increases
to a greater extent in acute liver diseases. Moreover, the values of mitochondrial aspartate aminotransferase
activity and the ratio of mitochondrial to total aspartate aminotransferase in alcoholic hepatitis are higher
than expected if so-called hepatic enzymes commonly measured in serum are considered. These results indi-
cate that there is significant mitochondrial damage in alcoholic hepatitis.
Klinische und diagnostische Bedeutung von Aspartataminotransferase-Isoenzymen im Serum von Patienten mit
Lebererkrankungen.
Zusammenfassung: Die Isoenzyme von Aspartataminotransferase im Serum wurden mit einer neuen und
einfachen immunchemischen Methode bei 123 Krankenhauspatienten mit verschiedenen Lebererkrankungen
bestimmt.
Unsere Ergebnisse zeigen die Nützlichkeit dieser Bestimmung für die Feststellung des Schweregrades der
Leberschädigung, besonders, wenn gleichzeitig andere mitochondriale Enzyme bestimmt werden. Während
einer Leberschädigung ist das cytoplasmatische Isoenzym in größerer Menge als das mitochondriale Isoenzym
nachweisbar. Dieses steigt jedoch bei akuten Lebererkrankungen an. Darüberhinaus sind die Werte für mito-
chondriale Aspartataminotransferase-Aktivität und das Verhältnis von mitochondrialer zu gesamter Aspar-
tataminotransferase bei alkoholbedingter Hepatitis höher als erwartet, wenn die sogenannten, üblicherweise
im Serum bestimmten Leberenzyme betrachtet werden. Die Ergebnisse zeigen, daß bei alkoholbedingter
Hepatitis eine bedeutende mitochondriale Schädigung besteht.
Introductioh
Serum total aspartate aminotransferase has been
,widely studied, äs an optimal index for hepatic dis-
eases. However, it is known that this index does not
necessarily QQincide with the intensity of liver cell
damage (1).
Recently, several studies have demonstrated the
presence of both cytoplasmic and mitochondrial as-
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partate aminotransferases (EC 2.6.1.1), (2—6),
which differ in their amino acid composition and in
their immunochemical and kinetics properties (7—
9).
As early äs 1967, Schmidt et al. (10) started to con-
sider the possible clinical usefulness of measuring of
these isoenzymes. Until recently, measurement of
these isoenzymes was not widely applied for clinical
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purposes, chiefly because the methods (electro-
phoresis (2-4), column chromatography (10, 11))
were tedious, slow, imprecise and inaccurate, and
not adaptable for routine use. Recent publications
(12—16) have described immunochemical proce-
dures, based on the use of antibodies directed
against the two aspartate aminotransferase isoen-
zymes. The introduction of these new immunochem-
ical methods has simplified and improved the sensi-
tivity of the isoenzymic assays.
In previous work (16, 17), we tried to establish a
possible relationship between the aspartate amino-
transferase isoenzyme composition of human serum
and the degree of hepatic damage. This paper repre-
sents the conclusive results of a study of 123 patients
with various liver diseases, performed over a period
of sixteen months.
Materials and Methods
123 patients were studied; these were admitted to the 4th Div-
ision of Medicine and to the Infectious Diseases Division of the
Civil Hospital of Brescia, over a period of sixteen months (1981—
1982). The patients were divided, on the basis of anamnestic, his-
tologic and diagnostic data, into the following groups:
(a) acute viral hepatitis (28 cases, mean age 30 ± 20 years);
(b) alcoholic hepatitis (30 cases, 48 ± 7 years);
(c) active chronic hepatitis (14 cases, 36 ± 10 years);
(d) persistent chronic hepatitis (14 cases, 34 ± 12 years);
(e) primary and secondary neoplastic disease of the liver (11
cases, 58 ± 9 years);
(f) hepatic cirrhosis (26 cases, 52 ± 9 years).
In addition, 50 healthy volunteers were studied in order to estab-
lish the reference level of aspartate aminotransferase isoenzymes
in serum. Serum samples were obtained from laboratory workers
with normal serum biochemical and haematological tests and
without clinical evidence of liver, pancreatic, cardiac and muscle
diseases (25 women and 25 men, whose ages ranged from 20 to 45
years, average 30 ± 6 years). The unhaemolysed sera were frozen
at —60 °C within 2 h of collection and used within two days. Sta-
bility studies confirmed that the activities of examined enzymes
and isoenzymes were unaltered during storage for this period.
The following examinations were carried out in duplicate on all
the subjects: aspartate aminotransferase (18), alanine amino-
transferase (18), -glutamyl transpeptidase (19), ornithine carba-
myl transferase (20) and glutamic dehydrogenase (21). Enzyme
activity concentrations are expressed in terms of U/1 serum (l Un-
it = l Substrate converted per minute under optimal condi-
tions) measured at 37 °C. An immunochemical method (15, 16)
was used for the determination of aspartate aminotransferase
isoenzymes: the serum specimen is incubated with sheep red
blood cells, which have anti-human soluble aspartate aminotrans-
ferase antibodies adsorbed to their surface; the cytoplasmic isoen-
zyme of aspartate aminotransferase is adsorbed on red cell, thus
permitting elimination of this isoenzyme by centrifugation. In the
surnatant the residual aminotransferase activity corresponds to
the mitochondrial isoenzyme and is determined with same meth-
odology described for the total enzyme (18). Cytosolic activity is
estimated by difference. A lyophilised serum, obtained from Poü
Industria Chimica, Milan, Italy, with a mean value of 130 U for
the mitochondrial enzyme and 1300 U/1 for the soluble isoen-
zyme, was used for quality control. Since no recognized reference
method exists for the determination of aspartate aminotransferase
isoenzymes, we have selected the immunoprecipitation technique
of Rej (13), involving anti-human soluble isoenzyme rabbit anti-
bodies, äs the comparative method for our procedure. Cofrelation
between the two techniqües was excellent, with * " value of 0.994
(y = 0.92x - 0.21).
All the enzymatic determinations, except ornithine carbamyl
transferase, were carried out on a Cobas Bio centrifügal analyzer
(F. Hoffman La Röche and Co., Ltd., Basle, Switzerland). The
ornithine cärbamyl transferase activity was determined by a man-
ual procedure (20), using a LKB 7400 Calculating Absorptiorhe-
ter (LKB Produckter AB, Bromma, Sweden). Since values for the
serum enzymes were not normally distributed, the statistical ana-
lyses were performed with non-parametric statistical tests
coxon rank-sum test) (22).
Results
The results of enzyme and isoenzyme determina-
tions, in different patients groups and in healthy vo-
lunteers, expressed äs median values, are summa-
rized in table l. Figüre l shows the levels of mito-
chondrial isoenzyme of aspartate aminotransferase
in various liver diseases.
The differences between the patient groups were not
always significant; the behaviour and discriminative
capacity of cytosolic isoenzyme are very similar to
those of total aspartate aminotransferase, while the
mitochondrial isoenzyme is a better discrimmator for
separating acute viral hepatitis from the other hepat-
ic diseases. In acute hepatitis, marked changes are
observed in the mitochondrial isoeiazyme levels: in
patients with higher relative proportions of mito-
chondrial isoenzyme, the recovery tended to be de-
layed, while in most of the patients with low values
of mitochondrial aspartate aminotransferase activity,
the liver function returned to normal within a few
weeks. The behaviour of this isoenzyme, in the
course of acute hepatitis, is the same äs that of the
alanine aminotransferase, ornithine carbamyl trans-
ferase and glutamic dehydrogenase. This is to be ex-
pected since ornithine carbamyl transferase and glu-
tamic dehydrogenase, äs well *as mitochondrial .as^
partate aminotransferase, are localized exclusively in
the mitochondrium and leak into serum only when
liver cells are severely damaged.
Important data emerged from the analysis of pa-
tients with alcoholic hepatitis: total transaminase ac-
tivities are only moderately raised, but considerably
higher proportions of mitochondrial aspartate ami-
notransferase are found in the serum. In this condi-
tion, the essential lesion is a focal liver cell necrosis
with polymorphonuclear leukocyte · Infiltrate and
varying degrees of fibrosis (23). "
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Tab. 1. Enzyme and isoenzyme median values*) in serum of patients with various hepatic diseases and in healthy volunteers.
Total aspartate aminotransferase
Soluble aspartate aminotransferase
Mitochondrial aspartate aminotransferase
Alanine aminotransferase
Ornithine carbamyl transferase
Glutamic dehydrogenase
γ-Glutamyltranspeptidase
(U/l)
(U/I)
(U/l)
(U/I)
(U/l)
(U/l)
(U/l)
Acute
viral
Hepatitis
387
352
29.5**)
592**)
68.5**)
19.8**)
146
Alcoholic
Hepatitis
62
55
7.1
36
26.0
12.0
249
Active
chronic
Hepatitis
241
223
9.0
159**)
18.1
12.1
58
Persist-
ent
chronic
Hepatitis
66
63
2.9
60
10.0
3.6
58
Liver
neo-
plasia
65
60
6.4
35
18.7
10.5
512
Hepatic
cirrhosis
62
62
0.7
24
5.0
2.2
79
Controls
17
17
0
13
5
1
11
.7
.0
.2
*) All values are expressed in U/l (see 'Materials and methods').
**) Significantly different value from other Hepatic diseases (p <0.01).
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Fig. 1. Mitochondrial aspartate aminotransferase levels in various liver diseases.
Fig re 2 shows the ratio between mitochondrial and
total aspartate aminotransferase in various hepatic
diseases: about 30% of alcoholic hepatitis cases
show values exceeding 14%, while in all other
groups it is considerably lower. This therefore helps
to discriminate between alcoholic hepatitis and all
other liver pathologies under consideration.
These results seem to demonstrate that there could
be a mitochondrial aspartate aminotransferase in-
duction by alcohol. Mitochondrial aspartate amino-
transferase values re higher than would be expected
from the corresponding histological necrotic pict re.
The hypothesis (24—26) that enzymatic induction is
a significant factor in the alcoholic liver diseases was
investigated by the contempor neous study of two
mitochondrial enzymes, glutamic dehydrogenase
and ornithine carbamyl transferase, which are notor-
iously associated with deep cellular damage (27, 28).
In alcoholic hepatitis, there is a positive correlation
between mitochondrial aspartate aminotransferase
and ornithine carbamyl transferase (r = 0.894; p
<0.001) and between mitochondrial aspartate ami-
notransferase and glutamic dehydrogenase (r =
0.600; p <0.001).
Thus, these results indicate significant mitochondrial
damage in alcoholic hepatitis, and it is unlikely that
the raised mitochondrial matrix enzymes represent
merely an adaptive response to the ethanol load.
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Fig. 2. The ratio (median values in percentage) between mitochondrial and total aspartate aminotransferase in hepatic diseases and in
healthy volunteers. The difference between alcoholic hepatitis and other hepatic diseases is statistically significant (p <0.05).
Solid triangle: liver cirrhosis and accidental trauma with wide haematomas of the pelvis and inferior limbs.
Discussion
Fleisher et al. (3, 4) found human serum to contain
two types of aspartate aminotransferase. This finding
was confirmed by subsequent enzymologic studies
(2,5,6), which demonstrated the existence of a cyto-
plasmic or soluble isoenzyme of aspartate amino-
transferase and a mitochondrial one. Later, other
authors (7, 8,29) reported that these two forms have
different immunochemical behaviour, due to slight
differences in their protein structures (9, 30).
The major component in normal sera is the cytoplas-
mic isoenzyme (median value, 17 U/l), while sera
from healthy people show very low activities of the
mitochondrial isoenzyme (median value, 0.7 U/l).
Our data confirm those of other authors (13,15,25),
who found small quantities of mitochondrial aspar-
tate aminotransferase in healthy subjects. The physi-
ological significance of these isoenyzmes is un-
known, but the presence of both isoenzymes in var-
ious organs suggests their importance in the aspar-
tate-malate shuttle, which is responsible for the
transport of reducing equivalents of nicotinainide
adenine dinucleotide through the mitochondrial
membrane. Moreover, if we consider that the two
enzymes are located in the cytoplasm and mitochon-
dria, respectively, then hepatic damage will release
more of the soluble thän the mitochondrial aspartate
aminotransferase into the bloodstream.
The presence of the latter in the blood reqüires mito-
chondrial damage, which usually occurs only in a
deep cellular necrosis, whereas the release of cyto-
solic isoenzyme is only due to an increase in permea-
bility of the cell membrane. Indeed, this happens in
various examined hepatic diseases (tab. 1): it is evi-
dent that mitochondrial isoenzyme levels increase
much more in acute liver pathology (fig. 1). In pa-
tients with acute viral hepatitis, the subjects showing
good clinical progress shöwed a relatively low value
of mitochondrial aspartate aminotransferase äctivity.
In contrast, recovery tended to be prolonged in pa-
tients with higher values of mitochondrial aspartate
aminotranferase. This fact seems to indicäte that the
determination of serum mitochondrial aspartate
aminotransferase äs an important index for judging
J. Clin. Chem. Clin. Biochem. / Vol. 22,1984 / No. 2
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the prognosis of acute liver diseases (31). In alcohol-
ic hepatitis, mitochondrial aspartate aminotransfe-
rase values were much higher than expected, when
so-called hepatic enzymes commonly measured in
serum and anamnestic and Histologie findings were
taken into consideration. Moreover, the ratio of mi-
tochondrial to total aspartate aminotransferase was
significantly higher when compared with non-alco-
holic liver diseases. Based on these facts, some au-
thors (24, 25) have hypothesized that high values of
mitochondrial aspartate aminotransferase in alco-
holic hepatitis may be due to an induction in hepatic
mitochondria by alcohol. In contrast, our conclusive
data show significant mitochondrial damage in this
liver pathology: mitochondrial aspartate amino-
transferase seems to be specifically related to liver
damage, in the same wäy äs ornithine carbamyl
transferase and glutamic dehydrogenase (27, 28); an
increase of mitochondrial aspartate aminotransfe-
rase in serum therefore indicates a more severe in-
jury of the hepatic cells. Furthermore, marked pa-
thological changes have been observed in mitochon-
dria of liver cells of alcoholics, due to the toxic effect
of ethanol and its metabolites (32, 33); electron mi-
croscopic studies show swollen mitochondria with
disorientated cristae (34). Also, in some cases, mus-
cle damage (alcoholic myopathy), resulting in leak-
age of enzymes from myocytes, could be partially re-
sponsible for the relatively elevated activity of mito-
chondrial aspartate aminotransferase in alcoholic se-
rum (35); but none of our patients with alcoholic he-
patitis had overt clinical heart disease or symptomat-
ic myopathy, which might have contributed to en-
zyme abnormalities. Therefore, we have shown the
advantages of mitochondrial aspartate aminotransfe-
rase äs a biochemical marker of liver necrosis.
Higher proportions of mitochondrial aspartate ami-
notransferase are found in the serum of patients with
acute liver diseases; higher activities of glutamic de-
hydrogenase and ornithine carbamyl transferase also
occur in the sera in these conditions. In particular,
the ratio of mitochondrial to total aspartate amino-
transferase seems to identify very well the character-
istic "necrotic type" condition named by Schmidt
(10), i.e. a slight increase of the enzyme levels con-
comitant with relatively high activities of mitochon-
drial enzymes.
The practical implications of these results are evi-
dent. The new immunochemical procedures for the
determination of aspartate aminotransferase isoen-
zymes are technically simple and specific, and the
levels of these enzymes are reliable index of the
presence or absence of liver cell necrosis. Estimation
of aspartate aminotransferase isoenzymes should
therefore be included in the investigation of hepatic
diseases. In particular, a knowledge of the serum
concentration of these isoenzymes could improve the
identification of patients with active alcoholic liver
disease, including those who are asymptomatic.
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